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Detailed study of changes in renal function after 
conversion from cyclosporine to azathioprine
L. B. H ilb ra n d s , A. J. H oitsm a , J. F. M. W etzels and R. A. P. Ko e n e
Department o f Medicine, Division o f Nephrology, University Hospital Nijmegen, 
Nijmegen, The Netherlands
Abstract. The renal dysfunction induced by cyclosporine (CsA) has been demonstrated to be at least 
partially reversible after cessation of CsA therapy. The time course and magnitude of changes in va­
rious parameters of renal function after CsA withdrawal have not been studied in detail. We exam­
ined 12 renal transplant patients immediately before and 1,2, and 4 weeks after replacement of CsA 
by azathioprine at 3 months after transplantation. Nine patients in whom CsA was continued during 
this period served as a control group. A significant increase in glomerular filtration rate ([GFR] 15 ± 
17%, p <0.01) occurred already in the first week after discontinuation of CsA. From 1 to 4 weeks 
after conversion, GFR did not significantly increase any further. A fall in serum creatinine (-7 ± 9%, 
NS) paralleled the rise in GFR (r = -0.76, p <0.01), but there was a further decrease of creatinine in 
the second to fourth week after conversion. Withdrawal of CsA induced a rise in serum magnesium 
in all patients (0.73 ± 0.13 vs 0.86 ± 0.12 mmol/1, p <0.001) as well as a marked decrease in the 
serum level of urate (0.39 ± 0.09 vs 0.33 ± 0.07 mmol/1, p <0.01) within one week. None of the ob­
served changes took place in the control group. In conclusion, a major improvement of GFR occurs 
within one week after cessation of CsA therapy. Changes in the serum levels of magnesium and 
urate appear to be the most responsive markers of the renal effects of CsA.
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Introduction are not available. We therefore performed a prospective
study to examine the rate of changes in renal function 
The immunosuppressive drug cyclosporine A (CsA) during the first four weeks following conversion from 
contributes greatly to the successful treatment of trans- CsA to azathioprine at three months after renal transplan- 
plant recipients and patients with auto-immune diseases, tation. In addition to GFR, various other indices of renal 
An important side effect of CsA is the impairment of function (such as tubular handling of sodium and uric 
renal function. Although long-term use of the drug may acid) were measured in order to identify the most sensi- 
result in irreversible renal injury, discontinuation of CsA tive markers of the renal effects of CsA. 
is usually followed by considerable recovery of renal 
function [Chapman et al. 1985]. This reversible compo­
nent of CsA-induced renal dysfunction has been ascribed Methods 
to preglomerular vasoconstriction [Conte et al. 1989,
Sabbatini et al. 1993], a functional effect that should Subjects 
cease immediately after CsA withdrawal. Several human
studies provide information on the degree of improve The study group consisted of 12 renal transplant
ment in creatinine clearance or glomerular filtration rate patients (10 M, 2 F; age 41 ± 14 years) in whom elective 
(GFR) that can be expected after cessation of CsA conversion from CsA to azathioprine was carried out at 
[Chapman et al. 1985, Versluis et al. 1987]. However, three months after transplantation as part of another study 
comprehensive data on the time course of these changes protocol (randomized prospective trial comparing con­
version from CsA to azathioprine with CsA monotherapy 
from three months after renal transplantation). Nine pa- 
-------  tients (7 M, 2 F; age 42 ± 12 years) who were allocated to
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weeks prior to the study) and diastolic blood pressure 
was below 110 mmHg. Patients who were using diuret-
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ics, xanthine derivatives, or nonsteroidal anti-inflamma-
tory were excluded. Furthermore, two
were excluded during the four-week study period be­
cause an acute rejection episode was diagnosed (the study
Gomerular filtration rate (GFR) and renal plasma 
flow (RPF) were measured using a continuous infusion 
technique. Renal clearances of inulin (polyfructosan, Inu- 
test®, Laevosan-Gesellschaft, Linz, Austria) and para-
and control population initi ally consisted of 13 and 9 aminohippuric acid (PAH) were used as markers of GFR
patients respectively). During the first three months after and RPF, respectively. After an equilibration period of
transplantation, immunosuppressive treatment consisted 90 min, urine was collected at 30 min intervals. Blood
of CsA (initial oral dose of 12 mg/kg/d, tapered to approx- samples were drawn at the midpoint of each urinary
imately 4 mg/kg/d in two divided doses) and prednisone collection period. Blood pressure and heart rate were
(20 mg/d at the time of the study) in all patients. In the recorded every three minutes with an automatic device
conversion group, CsA was replaced by azathioprine in a (Dinamap model 1846P, Critikon Inc., Tampa, FL, USA), 
dosage of 3 mg/kg/d. The prednisone dosage was tern- The mean values of five consecutive readings around the 
porarily increased from 20 to 25 mg/d during the first midpoint of each clearance period were used for analysis.
two weeks after conversion but was back on 20 mg/d The ation fraction (FF) was calculated as
during the following two weeks. In patients who contili- GFR/RPF X 100% and renal blood flow (RBF) was esti- 
ued on CsA, the dose of CsA was not changed and accord- mated using the formula RBF = RPF/( 1 - haematocrit). 
ing to our treatment protocol, the prednisone dosage Renal vascular resistance (RVR) was defined as mean
was reduced from 20 to 10 mg/cl during the four-week arterial pressure (MAP) divided by RBF and expressed in
study period. Six patients (4 in the conversion group and arbitrary units. Fractional excretions of sodium and uric
2 in the control group) used atenolol (50 to 100 mg once acid (FENn and FEUr) were calculated as their respective
daily) and 11 patients (4 in the conversion group and 7 in renal clearances (CNa and CUr) divided by GFR and
the control group) received the combination of atenolol expressed as percentage. Using the lithium clearance
and nifedipine (10 or 20 mg slow release tablets twice (CLI) as an approximate marker of proximal tubular sodi-
daily) as anti hypertensive therapy. The dose of these um and water reabsorption [Thomsen 1984, Boer et al. 
drugs was not changed during the study period. The 19951, the fractional proximal sodium reabsorption 
study was approved by the Hospital Ethics Committee (FPRNa) and fractional distal sodium reabsorption
and all patients gave written informed consent. (FDRNh) were estimated by the following calculations:
Study protocol
FPRNa «  ( 1 - CLI/GFR) X 100% and
FDRNn (i - c Na/cu) x ioo%.
In the conversion r Clearances of the various parameters were calcu
out on the day before discontinuation of CsA (at three lated for each of the three 30 min intervals and these
months after transplantation) and 1, 2, and 4 weeks after­
wards. Patients in the
measurements only at the first and last occasion of this
were The resulting 
clearance values were adjusted to a standard body surface
1.73 nr.
series, i.e. at 3 i 4 s after transplantation. All
experiments were performed from 9:00 a.m. till noon.
The patients were on a regular diet but were advised to Analytical procedures
4t , liquorice, or tobacco 
during the last nine hours preceding the measurements.
The evening preceding each experiment, 300 mg of lithi
um carbonate (8.1 mmol 
light breakfast on s 
ble, anti
n arrival in the ward, a
A sufficient
was
sample was drawn for
In serum or urine samples, PAH, inulin, creatinine,
assium, magnesium, uric acid, and bicarbo- 
orally. A nate were measured by standard techniques. Lithium was
by atomic absorption spectrophotometry. In 
is the hematocrit was determined by routine 
md whole blood CsA levels were meas-
al antibody against the CsA parent 
ar morning molecule using Abbott TDx (Abbott Laboratories, North
ured with a
■esis was attained by an Chicago, IL, USA).
oral water load of 10 ml






ucose at a rate of 400
il %
water. Except for s
y r iI
voiding in 'Ok
Data are reported as means ± SD unless stated
were analyzed with Wilcoxon’s test 
paired or unpaired observations when appropriate.
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Correlations were assessed by calculating Spearman’s icantly differed from that in the control group. RPF and 
correlation coefficient. A probability value less than 0.05 RVR showed an increase and decrease respectively, but 
was considered statistically significant. No correction for statistical significance was not achieved for the differ- 
comparison of multiple outcomes was applied. ence with the control group. Conversion from CsA to aza­
thioprine was not followed by a change in the filtration
fraction (0.22, 0.20, 0.20, and 0.22 at 0, 1, 2, and 4 weeks 
respectively). A fall in serum creatinine during the first 
week after conversion was followed by a further decrease 
Base-line values of blood pressure, renal hemody- during the subsequent 3 weeks, resulting in a significant 
namic parameters, and other indices of renal function did difference from base-line from 2 weeks after conversion, 
not differ between the conversion and control group At 1 and 4 weeks after conversion, serum creatinine 
(Tables 1 and 2). There were no differences between pa- had decreased in 9 and 11 of all 12 cases respectively, 
tients who used atenolol as the sole antihypertensive drug Blood pressure tended to decline after CsA withdrawal,
Results
(n = 6) and patients without antihypertensive therapy (n although the difference did not reach statistical signifi-
4) with respect to base-line values of the parameters cance.
given in Tables 1 and 2. However, when all patients who The time course of other potential indices of the
used nifedipine (n = 11) were compared to those who did renal effects of CsA are given in Table 2. The most com-
not (n = 10), the former group was characterized by a mon change during the first week after conversion was a
higher FENa (6.5 ± 2.8% vs 3.3 ± 0.8%, p <0.01), a lower rise in the serum magnesium level, which occurred in all
FPRNa (53.2 ± 11.3% vs 66.6 ± 7.1%, p <0.01), and a patients. In addition, there was a rapid and marked
lower FDRNa (86.4 ± 4.1% vs 90.0 ± 2.1%, p <0.05) at decrease in the serum level of urate. The fractional excre-
week 0. In the control patients, who continued to use tion of uric acid did not change after conversion from
CsA, the CsA trough levels remained constant (week 0: CsA to azathioprine (17 ± 8% at base-line vs 16 ± 8% at
161 ± 48 ng/ml, week 4: 176 ± 52 ng/ml; NS). Patients in 4 weeks). There was a slight decrease in FENa which
the conversion group had similar CsA levels at week 0 appeared to be due to an increase in the fractional distal
(176 ± 59 ng/ml; NS for difference versus control group). reabsorption of sodium. However, as mentioned above,
One week after discontinuation of CsA, GFR had tubular handling of sodium and lithium were influenced
improved in all but one patient. During the next three by the use of nifedipine. To circumvent this potential
weeks, a slight and statistically non-significant further source of bias, we repeated the analysis on tubular sodi-
increase in GFR was observed (Table 1). After four um handling after exclusion of 4 nifedipine users from
weeks, the change in GFR in the conversion group signif- the conversion group. As is shown in Table 3, in the
Table 1 Blood pressure, renal hemodynamic parameters, serum creatinine, and creatinine clearance in 12 renal transplant patients converted from 
CsA to azathioprine (Aza) and in control patients (n = 9); base-line values (week 0) and relative changes from base-line. The last column denotes the 
p-value for the between-groups comparison of changes at 4 weeks.
Weeks
0“ 1 2 4
P
Csa —> Aza vs CsA
Mean arterial pressure CsA —> Aza 113 ± 11 — 4 ± 8% - 4 ±7% — 5 ± 7% NS
(mmHg) CsA 111 ±5 — — - 2 ± 7%
G F R CsA —» Aza 55 ±18 + 3 5 ± 189bc +18 ± 26%h +18 ± 24 %b 0.036
(ml/min/1.73 nr) CsA 61 ± 15 — «D0» - 2 ± 17%.
R P F CsA —> Aza 267 ±117 +27 ± 43 %b +27 ± 35 %b +21 ±36% NS
(ml/min/1.73 m2) CsA 306 ± 92 •— - 3± 18%
R V R CsA > Aza 0.36 ± 0.22 -18±21%t' -18 ± 22%b -12 ±26% NS
(arbitrary units) CsA 0.25 ± 0.12 — + 4 ± 30%
Serum creatinine CsA —» Aza 125 ± 41 - 7 ± 9% - 1 1  ±  1 0 % c -13 ± 9%c 0 . 0 0 1
(jxmol/l) CsA 116 ±25 — — + 4 ±9%
Creatinine clearance CsA -» Aza 70 ±21 + 11 ±23%h 4-16 ± 38% +20 ± 44% NS
(ml/min/1.73 m2) CsA 79 ± 20 — smm - 3± 12%
" Base-line levels did not differ between both groups for any parameter. 
h p <0.05, e p <0.01 for differences versus base-line values.
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Table 2 Serum levels of potassium, bicarbonate, magnesium, and urate, and tubular handling of sodium in 12 renal transplant patients converted 
from CsA to azathioprine (Aza) and in control patients (n = 9); base-line values (week 0) and absolute changes from base-line, The last column de­
notes the p-value for the between-groups comparison of changes at 4 weeks.
Weeks
0» 1 2 4
P
Csa -
Sérum potassium CsA —> Aza 4.6 ± 0.4 0.1 ± 0.8 ■“ 0.1 :£ 0.5 - 0.3 ± 0.51 NS
(mmol/1) CsA 4.4 ± 0.5 — — 0.2 ± 0.3
Sérum bicarbonate CsA -> Aza 21.7 ±2.7 +2.4 ± 3.6h -l- 2.6 ± 2.3e + 1.4 ± 3.0 NS
(mmol/1) CsA 23.5 ±2.1 + 1.7 ± 3.1
Sérum magnésium CsA —> Aza 0.73 ±0.13 +0.12 ±0. H)1' +0.10 ±0.11" +0.12 ± 0.12e NvS
(mmol/1) CsA 0.80 ± 0.06 'lis tv t - +0.02 ± 0.09
Sérum urate CsA —» Aza 0.39 ± 0.09 -0.06 ± 0.04e -0.08 ± 0.061- -0.09 ± 0.061 0.002
(mmol/1) CsA 0.39 ± 0.05 ttr-M _ +0.03 ± 0.03
FEn. CsA —► Az.a 4.9 ± 3.2 “ 1.0 à: 2.0 - 1.4 ± 2.21’ — 1.2 ± 1.9 NS
(%) CsA 4.9 ± 1.5 TTP.11 K M - 0.8 ± 0.5
FPRnu CsA —> Aza 60.6 ± 12.5 -1.5 ± 10.6 + 0.7 ± 10.0 - 0.8 ± 12.9 NS
(%) CsA 58.2 ± 10.7 _ — + 5.0 ± 7.0
fd rn„ CsA —> Aza 88.2 ±4.3 +2.5 ±3.1" + 3.0 ±4.0b + 2.7 ± 3.2h NS
(%) CsA 88.1 ± 2.7 — — + 0.9 ±2.0
Azi\ vs CsA
M M ** .......................................................... n i m i i n
u Base-line levels did not differ between both groups for any parameter. 
h p <0.05,c p <0.01, d p <0.001 for differences versus base-line values.
Table 3 Tubular handling of sodium in 8 renal transplant patients who were converted from CsA to azathioprine and did not use nifedipine; base 
line values (week 0) and absolute changes from base-line.
# r n t i im i u n  i r r na
0








" p <0.05 for difference versus base-line value 
For abbreviations see text.
1
+0.1 ± 0.9
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-0.2 ± 1.0 
-5.7 ± 10.5 
+ 1.8 ± 3.2
«c a o  u m n ú H ftiw n
remaining 8 patients there was a slight decrease in FPRNtl Discussion 
at one week after conversion, while a significant increase
in FDRNa was lacking in this subgroup o f patients. Mean This controlled study of the changes in renal fune
ingful comparisons with the control group were not pos- lion that occur after discontinuation of CsA demonstrates 
sible since only two members of this group did not use that these changes largely take place during the first week
following cessation of the drug. At one week after con- 
The relative change in serum creatinine showed a version, GFR had improved with 15% and in the ensuing 
significant correlation with the relative change in GFR weeks only a minor, non-significant, further increase in
(at 1 week: r = -0.76, p <0.01; at 4 weeks: r -0.57, p (¡MW GFR was observed. As expected from literature data* the
0.055). Although the improvement in renal function and increase in GFR was accompanied by a rise in RPF and a 
the decrease of serum urate were o f equal magnitude, decrease in RVR [Curtis et al. 1986, Zietse et al. 1994].
there was no significant correlation between Accordingly, our the by
changes. Likewise, the change in serum magnesium was others that renal vasoconstriction is involved in the rever- 
not correlated with the change in either GFR or serum sible form of CsA-induced renal dysfunction [Conte et al.
• 4
creatinine. 1989, Sabbatini et al. 19931. The fall in serum creatinine
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lasted slightly longer than the rise in GFR, which may were the most sensitive markers of the acute renal effects
partly be due to the time needed to achieve a new steady of CsA. The mechanisms by which CsA changes the
state of the serum creatinine level after a change in crea- serum levels of magnesium and urate are not quite clear,
tinine clearance. The relevance of these findings is that in Theoretically, hyperuricemia may result from a decrease
clinical as well as in investigational circum- in the filtered load of urate with impaired GFR, from an 
stances the outcome of CsA withdrawal with regard to independent effect of CsA on tubular urate transport, or 
renal function can already be judged reliably after two from both of these factors. The lack of correlation be-
When tween the decrease in serum urate and the increase in
the time of evaluation becomes longer, the chance in- GFR in our patients suggests that the improvement of 
creases that measurement of the effects of CsA withdrawal renal function is not the sole explanation for the reduc-
conversion to azi
conversion
becomes disturbed by other factors. One of these con- tion of urate
founding factors in renal transplant patients can be a prine. Moreover, in other studies it was found that urate
change in renal function due to an acute rejection episode levels were higher in CsA-treated patients than in those
which sometimes occurs already in the first month after receiving azathioprine for any given degree of renal func-
CsA to azathioprine [Hoitsma et al. tion [Chapman et al. 1985, Versluis et al. 1988, Lin et al.
1989]. It has therefore been suggested that CsA specifi-
Generalization of the results may be limited by the cally decreases tubular secretion or increases tubular
fact that the study was carried out in CsA-treated patients reabsorption of urate [Lin et al. 1989, Noordzij et al.
with rather well functioning grafts. Some selection-bias 1991]. Since we did not observe an increase in FElJr after
may have occurred in this respect since it has been our cessation of CsA, our data do not support this hypothesis,
policy to replace CsA by azathioprine prematurely in although an irreversible change in the tubular handling of
patients in whom poor graft function was suspected to be urate due to CsA treatment, as suggested by Noordzij et
worsened further by CsA-related nephrotoxicity. In addi- al., cannot be excluded. An increased renal clearance of
tion, the fluid load and the supine position of the patients magnesium in CsA-treated patients has been demonstrat-
may have raised the measured GFR to some extent. ed repeatedly [June et al. 1985, Barton et al. 1987, Scoble
In previous studies, a decrease in the fractional clear- et al. 1990], but the tubular site and mechanism of altered 
ance of lithium (FELi) has been suggested to be a sensi- magnesium transport remain unknown.
tive marker of CsA-induced renal dysfunction [Dieperink In summary, the improvement in GFR that can be
et al. 1987, Vincent et al. 1988, Propper et al. 1990]. At expected after discontinuation of CsA is largely attained 
first sight, we were not able to confirm these findings as within one week. A rapid and marked increase in serum 
the fractional proximal sodium reabsorption (which was magnesium and decrease in serum urate level are the
calculated by the formula 100-FELi) did not change after most consistent
discontinuation of CsA. appei to conversion from CsA to azathioprine in renal transplant
pintroduced by treatment with the calcium antagonist nife­
dipine in four patients. Use of nifedipine during CsA 
therapy was associated with higher levels of FENa and 
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